1
Matsumoto Takahiro, Kori Masakuni, Miyazaki Junichi, Kiyota Yoshihiro: (Ja) アミド化合物, (En) Amide compound. Takeda Pharmaceutical Company, Matsumoto Takahiro, Kori Masakuni, Miyazaki Junichi, Kiyota Yoshihiro, KAWAMIYA Osamu, May 26, 2006: WO/2006/054652 (20 worldwide citation)

(EN) An FAAH inhibitor; and a preventive/therapeutic agent for cerebrovascular disorders and a preventive/therapeutic agent for sleep disorders which each contains the inhibitor. The FAAH inhibitor is a compound represented by the formula (I0): (wherein Z represents oxygen or sulfur; R1 represents o ...


2
Shirai Junya, Matsumoto Takahiro, Kamo Izumi: (Ja) ベンゾオキサゼピン誘導体およびその用途, (En) Benzoxazepine derivatives and use thereof. Takeda Pharmaceutical Company, Shirai Junya, Matsumoto Takahiro, Kamo Izumi, TAKASHIMA Hajime, September 12, 2008: WO/2008/108445 (19 worldwide citation)

(EN) Compounds represented by the general formula (I) wherein each symbol is as defined in the description [with the proviso that 9-chloro-7-(1,1-dimethylethyl)-2,3,4,5-tetrahydro-1,4-benz-oxazepine and N-[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1,4- benz- oxazepin-7-yl)-5-oxazolidinyl]methyl]acetamide ar ...


3
Johno Masahiro C O Corporate R, Yui Tomoyuki C O Corporate Res, Matsumoto Takahiro C O Corpora, Arai Yoshihisa C O Corporate R: Anti-ferroelectric liquid crystal composition and liquid crystal display device.. Mitsubishi Gas Chemical Co, February 9, 1994: EP0582468-A1 (18 worldwide citation)

An anti-ferroelectric liquid crystal composition consisting essentially of an anti-ferroelectric liquid crystal (A) and a ferrielectric liquid crystal (B) shows a low threshold voltage so that the driving voltage can be decreased, and the composition can give a liquid crystal display device utilizin ...


4
Matsumoto Takahiro, Kori Masakuni, Miyazaki Junichi, Kiyota Yoshihiro: Amide compound. Takeda Pharmaceutical, August 1, 2007: EP1813606-A1 (18 worldwide citation)

There is provided a FAAH inhibitor and a prophylactic or therapeutic agent for cerebrovascular disorders or sleep disorders comprising it. The prophylactic or therapeutic agent comprises a compound of the formula (I 0 ): wherein Z is oxygen or sulfur; R 1 is aryl which may be substituted, or a heter ...


5
Maehara Naoyoshi, Suenaga Haruo, Sakamoto Kazuho, Yamaguchi Kimiaki, Bessyo Daisuke, Niwa Takashi, Matsumoto Takahiro, Yoshino Koji Takanoharaeki: High-frequency heating apparatus.. Matsushita Electric, February 1, 1989: EP0301805-A1 (16 worldwide citation)

A high-frequency heating apparatus comprises a semiconductor power converter (33) which is supplied with electric power from a commercial power supply, etc., a radio wave radiation section (32) which is energized by the semiconductor power converter (33), a control section (34) which controls the op ...


6
Matsumoto Takahiro, Kamo Izumi, Nomura Izumi: Tricyclic heterocyclic compound and use thereof. Takeda Pharmaceutical Company, Matsumoto Takahiro, Kamo Izumi, Nomura Izumi, TAKASHIMA Hajime, January 17, 2008: WO/2008/007661 (14 worldwide citation)

Disclosed is a tricyclic heterocyclic compound having a serotonin 5-HT2C receptor activating effect and the like. Specifically disclosed is a serotonin 5-HT2C receptor activator containing a compound represented by the formula (I) below, a salt thereof or a prodrug thereof. (I) (In the formula, the ...


7
Bessyo Daisuke, Maehara Naoyoshi, Nakabayashi Yuji, Matsumoto Takahiro: High frequency heating apparatus utilizing inverter power supply.. Matsushita Electric, April 1, 1992: EP0477633-A1 (13 worldwide citation)

A high frequency heating apparatus which comprises a unitary structure comprising a magnetron (12) for generating a microwave, an inverter power supply (11) for supplying a high voltage electric power to the magnetron (12), and a cooling unit (26) for cooling the magnetron (12) and the inverter powe ...


8
Ogawa Wakoto, Kobayashi Toshiro, Sueda Ninoru, Matsumoto Takahiro, Imai Tetsuya, Shirogane Shigenori, Shiota Hiroshi, Uchida Toshiuki: Hydrogen separation member. Mitsubishi Heavy, September 24, 1997: EP0796647-A1 (12 worldwide citation)

A hydrogen separation membrane has a hydrogen-permeable metal foil laminated to a porous metal support. The metal support comprising a laminate of metal-reinforcing plates each having a plurality of hydrogen-flow-through holes. The metal-reinforcing plates have rectangular or similarly shaped holes ...


9

10
Matsumoto Takahiro, Katayama Nozomi, Mabuchi Hiroshi: Tyrosine phosphatase inhibitors. Takeda Chemical Industries, February 19, 2003: EP1284260-A1 (12 worldwide citation)

A compound of the formula (I): wherein X1 and X2 are the same or different and each is a bond or a spacer having 1 to 20 atom(s) in the main chain; one of R1 and R2 is a cycle group having substituent(s) selected from 1) an optionally substituted carboxy-C1-6 alkoxy group and 2) an optionally substi ...